VEGFA and esophageal squamous cell carcinoma: Endostatin and bevacizumab have already been applied in advanced ESCC treatment as anti-angiogenesis drugs through inhibiting VEGF cascade, cell proliferation of endothelial cells, and vessel development [28,29].